StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Regeneron Pharma (REGN) Thoughts After Speaking with Management - Truist Securities
January 12, 2021 6:52 AM
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $770.00 price target on Regeneron Pharma (NASDAQ: REGN) after speaking ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments